MacroGenics Inc (NASDAQ:MGNX) SVP Eric Blasius Risser sold 1,000 shares of MacroGenics stock in a transaction that occurred on Monday, March 12th. The shares were sold at an average price of $31.08, for a total transaction of $31,080.00. Following the sale, the senior vice president now owns 10,100 shares in the company, valued at approximately $313,908. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Eric Blasius Risser also recently made the following trade(s):
- On Friday, March 2nd, Eric Blasius Risser sold 4,000 shares of MacroGenics stock. The stock was sold at an average price of $30.00, for a total transaction of $120,000.00.
- On Wednesday, February 28th, Eric Blasius Risser sold 1,000 shares of MacroGenics stock. The stock was sold at an average price of $25.01, for a total transaction of $25,010.00.
- On Wednesday, January 24th, Eric Blasius Risser sold 3,000 shares of MacroGenics stock. The shares were sold at an average price of $22.50, for a total transaction of $67,500.00.
Shares of MacroGenics stock opened at $22.59 on Friday. MacroGenics Inc has a 12-month low of $14.36 and a 12-month high of $32.74.
MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.58 by $0.22. The company had revenue of $152.36 million during the quarter, compared to analyst estimates of $152.59 million. MacroGenics had a negative return on equity of 8.22% and a negative net margin of 12.44%. equities analysts predict that MacroGenics Inc will post -4.48 earnings per share for the current fiscal year.
Several brokerages have recently issued reports on MGNX. BidaskClub downgraded shares of MacroGenics from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. Zacks Investment Research raised shares of MacroGenics from a “sell” rating to a “hold” rating in a report on Tuesday, February 13th. TheStreet raised shares of MacroGenics from a “d” rating to a “c+” rating in a report on Tuesday, March 27th. Cowen reiterated a “buy” rating on shares of MacroGenics in a research report on Wednesday, January 24th. Finally, ValuEngine upgraded shares of MacroGenics from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $30.25.
A number of institutional investors have recently added to or reduced their stakes in MGNX. Parametric Portfolio Associates LLC acquired a new position in MacroGenics during the second quarter worth $203,000. Teacher Retirement System of Texas acquired a new position in MacroGenics during the fourth quarter worth $225,000. MetLife Investment Advisors LLC acquired a new position in MacroGenics during the fourth quarter worth $281,000. Private Capital Advisors Inc. bought a new stake in shares of MacroGenics during the fourth quarter worth $332,000. Finally, Virtus Fund Advisers LLC bought a new stake in shares of MacroGenics during the fourth quarter worth $343,000. Hedge funds and other institutional investors own 91.13% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Insider Selling: MacroGenics Inc (MGNX) SVP Sells 1,000 Shares of Stock” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/macrogenics-inc-mgnx-svp-eric-blasius-risser-sells-1000-shares-of-stock.html.
MacroGenics, Inc, a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.